Neurobiology of Bipolar Disorder (BD) and Major Depressive Disorder (MDD) - A Comprehensive Review

1. Overview and Epidemiology

• MDD: Lifetime risk ~19% in the US; 8.3% annual prevalence; leading global cause of disability
• BD: Lifetime prevalence ~1% worldwide; equal sex distribution; relatively constant cross-culturally
• Both disorders are complex, polygenic conditions shaped by gene-environment interactions, with no single unifying cause

2. Genetic Basis

2.1 Heritability

2.2 Genome-Wide Association Studies (GWAS)

• Polygenic architecture underlies BD with common risk variants implicating neurobiological and developmental pathways
• BD I and BD II show distinct genetic architectures (subtype-specific GWAS signals)
• Polygenic risk scores (PRS) from the latest GWAS may have clinical utility when combined with other risk factors
• Genes at common-variant loci are enriched for rare variation, suggesting a continuum of genetic risk

2.3 Mendelian Randomization - Inflammatory Proteins

• TNFSF12 (TNF superfamily member 12) causally increases risk of MDD
• FGF23 and IL-20 are protective against MDD
• CXCL5, TRANCE, CCL7 are protective against BD
• This provides direct genetic evidence linking specific inflammatory proteins to psychiatric risk - a major advance over earlier epidemiological associations

3. Neurotransmitter Systems

3.1 Monoamine Hypothesis (Classical Framework)

• Serotonin (5-HT): Depletion of serotonin has long been linked to depressive symptoms. SSRIs (fluoxetine, sertraline, paroxetine) selectively inhibit the serotonin transporter (SERT), increasing synaptic 5-HT. SNRIs block both SERT and the norepinephrine transporter (NET).
• Norepinephrine (NE): Dysregulation of noradrenergic pathways (locus coeruleus projections to forebrain, hippocampus, amygdala) contributes to low energy, poor concentration, and cognitive blunting in depression.
• Dopamine (DA): Impaired dopaminergic reward circuitry (ventral tegmental area → nucleus accumbens, prefrontal cortex) underlies anhedonia, loss of motivation, and decreased goal-directed behavior in MDD.

3.2 Glutamate/NMDA Receptor System

• NMDA receptor hypofunction in prefrontal cortical circuits leads to loss of excitatory synaptic strength and dendritic spine atrophy
• Excess glutamate activity can be neurotoxic, and perisynaptic NMDA receptor activation (as opposed to synaptic) promotes depression-like states
• Ketamine (an NMDA antagonist) produces antidepressant effects within hours, shifting understanding of depression away from purely monoaminergic models
• AMPA receptors are now under intense investigation: A 2025 study (Tsugawa et al., Front Neural Circuits 2025) used machine learning to differentiate BD from MDD based on AMPA receptor distribution patterns, highlighting that differential glutamatergic receptor profiles may underlie the two conditions.

3.3 GABA

4. Neural Circuit Abnormalities

4.1 Prefrontal Cortex (PFC) - Amygdala Dysregulation

• Amygdala hyperactivation: Heightened basal amygdala activity in response to threatening and neutral stimuli in both MDD and BD. In mania specifically, amygdala is hyperactive with reduced PFC constraint.
• DLPFC/VLPFC hypofunction: The dorsolateral PFC (DLPFC) and ventrolateral PFC (VLPFC) show reduced activation in depression, impairing cognitive control over negative emotions.
• Animal lesion studies confirm that PFC projections to the basal amygdala are necessary for cognitive suppression of aversive information.

4.2 Anterior Cingulate Cortex (ACC)

• Increased glucose metabolism and blood flow in Cg25 are among the most replicated neuroimaging findings in depression
• Successful SSRI treatment correlates with decreased Cg25 activity
• Cg25 is the primary target for deep brain stimulation (DBS) in treatment-resistant MDD - ongoing UCSF trials include closed-loop DBS for treatment-resistant bipolar depression
• The caudal ACC (cognitive control subdivision) connects with DLPFC and posterior cingulate cortex; dysfunction contributes to cognitive impairment in depression.

4.3 Resting-State Network Disruption in BD

• Default Mode Network (DMN): Reduced intrinsic connectivity - the DMN (active during self-referential thought) is dysfunctional, linked to rumination and mood dysregulation
• Salience Network (SAN): Disrupted - the SAN normally determines what receives attention; dysfunction explains abnormal emotional salience in BD
• Central Executive Network (CEN): Reduced connectivity, underlying cognitive deficits
• Key nodes with diagnostic importance: posterior cingulate cortex (PCC), anterior insula (AI), postcentral gyrus, and precuneus - these differentiate BD from other disorders

4.4 Reward Circuit Dysfunction

• MDD: Hypoactive reward circuit → anhedonia, anergia, loss of motivation
• BD mania: Hyperactive reward circuit → excessive goal-directed behavior, hypersexuality, reckless spending, euphoria
• The lateral habenula (the "anti-reward center") shows hyperactivation in depression - it inhibits dopamine and serotonin neurons; ketamine may work in part by blocking burst firing in the habenula

5. Neuroendocrine Dysregulation - HPA Axis

5.1 HPA Axis Hyperactivity in MDD

• Elevated urinary free cortisol
• Elevated CRH in CSF
• Non-suppression of ACTH in the dexamethasone suppression test (DST)
• Elevated basal and diurnal cortisol levels (documented in ~50% of MDD patients)
• HPA dysregulation is especially pronounced in psychotic depression

5.2 Cortisol and Hippocampal Damage

• Glucocorticoid receptors are expressed at high density in the hippocampus
• Sustained cortisol binding → suppresses BDNF (brain-derived neurotrophic factor) transcription → hippocampal atrophy
• Hippocampal volume loss correlates with duration of untreated depressive episodes
• Because the hippocampus provides inhibitory feedback to CRH neurons in the hypothalamus, hippocampal damage impairs HPA axis shut-off → a positive feedback (vicious) cycle maintaining depression

5.3 Thyroid and Sex Steroids

• Up to 25% of depressed patients have abnormal thyroid function (blunted TSH response to TRH; elevated T4 during depression)
• Estrogen deficiency (postpartum, perimenopause) contributes to depression in women
• Testosterone deficiency in men can cause depressive symptoms; hormone replacement may improve mood

6. Neuroplasticity and BDNF - The Neurotrophic Hypothesis

• BDNF is reduced in the hippocampus and prefrontal cortex in MDD
• Antidepressants (all classes) ultimately increase BDNF transcription via downstream signaling (CREB phosphorylation via cAMP pathway) - this takes 2-4 weeks, explaining the treatment delay
• BDNF promotes dendritic branching, synaptogenesis, and adult neurogenesis in the dentate gyrus
• Stress and glucocorticoids inhibit hippocampal neurogenesis; SSRIs increase it in rodents
• BDNF Val66Met polymorphism (reduced activity-dependent BDNF secretion) is associated with increased risk of mood disorders

• MDD is characterized by loss of excitatory synapses and dendritic spine atrophy in the prefrontal cortex
• Ketamine, psychedelics (psilocybin), and ECT all converge on rapid structural synaptic remodeling - growth of dendritic spines in cortical pyramidal neurons
• This occurs within hours, preceding clinical improvement
• rTMS also appears to produce structural neural plasticity
• The common mechanism may be restoration of excitatory synaptic tone in PFC circuits that are chronically weakened by stress

7. Neuroinflammation - Emerging Framework

• Microglial activation: Pro-inflammatory microglia release IL-1β, IL-6, TNF-α → impair monoamine synthesis, promote glutamate excitotoxicity, damage the BBB
• Cytokine signaling: Elevated IL-6, IL-1β, TNF-α, CRP in serum of depressed patients. Notably, TNFSF12 is genetically linked to increased MDD risk.
• Kynurenine pathway: Inflammatory cytokines activate indoleamine 2,3-dioxygenase (IDO), shunting tryptophan away from serotonin synthesis toward kynurenine → quinolinic acid (an NMDA agonist, neurotoxic) and kynurenic acid (neuroprotective). Net effect: reduced serotonin + glutamate receptor overactivation.
• Blood-brain barrier (BBB) dysfunction: Chronic stress and cytokines increase BBB permeability, allowing peripheral immune cells and molecules to enter the CNS
• HPA-inflammation bidirectionality: Cortisol should suppress inflammation (negative feedback), but chronic stress produces glucocorticoid resistance in immune cells, paradoxically maintaining inflammatory tone

8. Bipolar Disorder: Specific Neurobiological Features

8.1 Cycling Mechanism and Circadian Biology

• Circadian clock gene disruption: CLOCK, BMAL1, and Per1/Per2 mutations are associated with BD. Lithium stabilizes circadian rhythms partly by inhibiting GSK-3β, which phosphorylates clock proteins.
• Monoamine systems (5-HT, NE) show diurnal variation tightly coupled to the sleep-wake cycle; disruption of this coupling may trigger cycling
• Sleep architecture abnormalities are both a symptom and a trigger of cycling (sleep deprivation can precipitate mania)

8.2 GSK-3β and the Wnt Signaling Pathway

• GSK-3β is a serine/threonine kinase with multiple substrates including clock proteins, β-catenin (Wnt pathway), and CREB
• Inhibition of GSK-3β by lithium promotes neuroprotection, decreases apoptosis, and stabilizes circadian rhythms
• This is distinct from the monoamine mechanisms of antidepressants, explaining lithium's unique efficacy in BD (Kandel 6e, p. 1567)

8.3 Gray Matter Volume Dynamics

• Manic episodes → gray matter volume increases (possibly reflecting neuroinflammatory changes, edema, or compensatory mechanisms)
• Depressive episodes → gray matter volume decreases (possibly reflecting synaptic pruning, apoptosis from prior inflammatory episodes)
• This dynamic, episode-dependent gray matter change confirms that BD is not static neuroprogression but involves reversible as well as potentially permanent structural changes
• Underscores the need for longitudinal, not cross-sectional, approaches to understanding BD neurobiology

8.4 BD vs MDD - Neurobiological Distinctions

9. Gut-Brain Axis

• Vagal nerve signaling
• Microbial metabolites (short-chain fatty acids) modulating neuroinflammation
• Kynurenine pathway modulation
• HPA axis regulation

10. Treatments and Neurobiological Mechanisms

10.1 Antidepressants (MDD and Bipolar Depression)

10.2 Ketamine / Esketamine (Major Recent Advance)

• Esketamine (Spravato) is FDA-approved for treatment-resistant MDD and MDD with suicidal ideation
• Works within hours via NMDA receptor blockade → downstream AMPA receptor activation → BDNF release → mTORC1-dependent synaptogenesis in PFC
• Multiple 2024-2025 reviews (Krystal et al., Neuropsychopharmacology 2024, PMID 37488280; Liao et al., Nat Rev Neurosci 2025, PMID 39558048) confirm that dendritic spine growth in cortical pyramidal neurons is a core mechanism
• A 2025 systematic review (Kwasny et al., Eur Neuropsychopharmacol 2024, PMID 38917771) evaluated ketamine specifically for anhedonia in unipolar and bipolar depression - showing particular promise for this treatment-refractory symptom

10.3 Mood Stabilizers in BD

• Lithium: Inhibits GSK-3β, inositol monophosphatase (IP1Pase), and adenylyl cyclase; regulates clock genes; neuroprotective (may actually increase hippocampal gray matter volume with long-term use)
• Valproate: Sodium channel blockade, GABA enhancement, histone deacetylase inhibition (epigenetic effects), inositol depletion
• Lamotrigine: Sodium/calcium channel blockade, reduces glutamate release; especially effective for bipolar depression
• Carbamazepine: Sodium channel blocker; does not inhibit monoamine transporters (unlike TCAs)

10.4 Neuromodulation (Recent Advances)

• ECT: Most effective intervention for severe MDD and mania; massive neurotransmitter release → gene expression changes → neural plasticity. Mechanism remains incompletely understood.
• rTMS: Non-invasive stimulation of DLPFC (left-sided excitatory protocols for depression); FDA-approved; 2024-2025 meta-analyses confirm improvement in depression + sleep (Qiao et al., J Psychiatr Res 2024, PMID 38905761)
• Deep Brain Stimulation (DBS): Subgenual ACC (Area 25) as target for treatment-resistant MDD; UCSF is running closed-loop (responsive) DBS trials specifically for treatment-resistant bipolar depression using the NeuroPace RNS system
• Vagus Nerve Stimulation (VNS): FDA-approved for treatment-resistant depression; mechanism involves NE and serotonin pathway modulation

10.5 Psychedelics (Emerging)

• Rapid dendritic spine growth (similar to ketamine)
• "Default mode network" disruption and subsequent reorganization
• Anti-inflammatory effects
• FDA breakthrough therapy designation for MDD and treatment-resistant depression

11. Omics and AI: The New Frontier

• Proteomics, metabolomics, and transcriptomics are identifying biomarker panels that may enable objective diagnosis
• Machine learning applied to neuroimaging (fMRI, EEG) is beginning to achieve clinically relevant accuracy for BD vs MDD differentiation
• Brain organoids (lab-grown "mini brains") from patient iPSCs are being used to model BD pathophysiology and test drugs - an extraordinary recent advance (2025 APL Bioengineering study)
• AI-based EEG pattern recognition has shown promise in identifying BD-specific oscillatory signatures

12. Global Burden Update (2026)

Summary of Key Neurobiological Themes

1. Circuit-level: Hypofrontal PFC → amygdala hyperactivity is the core circuit dysfunction in both conditions; BD shows additional reward circuit hyperactivation in mania
2. Neurotransmitter: Monoamine deficit (classical) + glutamate/NMDA imbalance (modern) + GABA hypofunction
3. HPA axis: Cortisol excess damages hippocampus → BDNF depletion → impaired neurogenesis → feedback failure
4. Neuroinflammation: Microglial activation + cytokine dysregulation + kynurenine pathway diversion - especially in treatment-resistant depression and BD
5. Neuroplasticity: Loss of dendritic spines and excitatory synapses in PFC is central; all effective treatments (SSRIs, ketamine, ECT, rTMS, psychedelics) restore this plasticity
6. Genetics: Polygenic architecture with GWAS-identified loci in neurobiological/developmental pathways; BD subtypes have distinct genetic signatures
7. Circadian biology: Especially important in BD; clock gene disruption → cycling; lithium stabilizes circadian system via GSK-3β
8. Gut-brain axis and omics: Emerging research frontiers with genuine therapeutic potential

• Kandel ER. Principles of Neural Science 6e, Chapter 61 (Mood and Anxiety Disorders), pp. 1549-1570
• Katzung BG. Basic and Clinical Pharmacology 16e, Chapter 30
• O'Connell KS et al. Biol Psychiatry 2025. PMID 40456304 - Genomics of BD
• Liao C et al. Nat Rev Neurosci 2025. PMID 39558048 - Structural plasticity and rapid antidepressants
• Salcudean A et al. Biomolecules 2025. PMID 40305200 - Neuroinflammation in depression
• Sun S et al. Neuroscience 2025. PMID 40328348 - Large-scale network alterations in BD
• Dong Z et al. Transl Psychiatry 2025. PMID 41429762 - Mendelian randomization of inflammatory proteins